We tested whether an ionization chamber array (ICA) and a one-dimensional water scanner (1DS) could be used instead of a three-dimensional water scanning system (3DWS) for acceptance testing and commissioning verification of the Varian Halcyon-Eclipse Treatment Planning System (TPS). The Halcyon linear accelerator has a single 6-MV flattening-filter-free beam and a nonadjustable beam model for the TPS. Beam data were measured with a 1DS, ICA, ionization chambers, and electrometer. Acceptance testing and commissioning were done simultaneously by comparing the measured data with TPS-calculated percent-depth-dose (PDD) and profiles. The ICA was used to measure profiles of various field sizes (10-, 20-, and 28 cm2 ) at depths of dmax (1.3 cm), 5-, 10-, and 20 cm. The 1DS was used for output factors (OFs) and PDDs. OFs were measured with 1DS for various fields (2-28 cm2 ) at a source-to-surface distance of 90 cm. All measured data were compared with TPS-calculations. Profiles, off-axis ratios (OAR), PDDs and OFs were also measured with a 3DWS as a secondary check. Profiles between the ICA and TPS (ICA and 3DWS) at various depths across the fields indicated that the maximum discrepancies in high-dose and low-dose tail were within 2% and 3%, respectively, and the maximum distance-to-agreement in the penumbra region was <3 mm. The largest OAR differences between ICA and TPS (ICA and 3DWS) values were 0.23% (-0.25%) for a 28 × 28 cm2 field, and the largest point-by-point PDD differences between 1DS and TPS (1DS and 3DWS) were -0.41% ± 0.12% (-0.32% ± 0.17%) across the fields. Both OAR and PDD showed the beam energy is well matched to the TPS model. The average ratios of 1DS-measured OFs to the TPS (1DS to 3DWS) values were 1.000 ± 0.002 (0.999 ± 0.003). The Halcyon-Eclipse system can be accepted and commissioned without the need for a 3DWS.
Keywords: Halcyon linear accelerator; acceptance and commissioning; ionization chamber array.
© 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.